Table 1.
Patient and tumour characteristics in a Scandinavian population-based cohort of metastatic colorectal cancer patients with available status on tumour-infiltrating CD3 and CD8 lymphocytes and CD68 macrophages (n = 448).
| Characteristics | Missing, n | |
|---|---|---|
| Age in years, median, range | 70 (24, 96) | |
| Age >75 years, n (%) | 152 (34) | |
| Female, n (%) | 226 (50) | |
| PS ECOG >1, n (%) | 149 (33) | |
| Right-sided, n (%) | 173 (39) | 7 |
| >1 metastatic site, n (%) | 259 (58) | |
| Synchronous metastases, n (%) | 241 (54) | |
| ALP high, n (%) | 218 (55) | 53 |
| Primary tumour resected, n (%) | 411 (92) | |
| Tumour grade 3, n (%) | 93 (22) | 15 |
| Mutations, n (%) | ||
| KRAS | 200 (46) | 15 |
| BRAFV600E | 91 (20) | |
| NRAS | 17 (4) | 50 |
| TP53 | 215 (54) | 50 |
| APC | 139 (35) | 50 |
| PIK3CA | 81 (20) | 50 |
| SMAD4 | 47 (12) | 50 |
| MSI, n (%) | 35 (8) | 1 |
| CDX2 loss, n (%) | 83 (19) | 2 |
| CD3 density, median, mean, 95% CI | 59.58, 123.36, (106.25, 140.47) | |
| CD8 density, median, mean, 95% CI | 40.03, 92.31, (79.08, 105.53) | |
| CD68 density, median, mean, 95% CI | 40.82, 115.21, (97.61, 132.81) | |
| Secondary metastatic surgery, n (%) | 33 (7) | 1 |
| Adjuvant chemotherapy | 67 (15) | |
| First-line chemotherapy, n (%) | 280 (63) | |
| Combination, n (%) | 216 (77) | |
| Monotherapy, n (%) | 64 (23) | |
| OS in months, median, 95% CI | 18 (15.11, 20.89) | |
| PFS in months, median, 95% CI | 8 (7.07, 8.63) | |
| BSC only, n (%) | 167 (37) | |
| OS in months, median, 95% CI | 3 (2.13, 3.87) | |
n number of patients, CI confidence interval, PS ECOG performance status score developed by Eastern Cooperative Oncology Group, Right-sided site of primary colon cancer in ascending colon and transversum, Left-sided site of primary colon cancer in the descending colon, sigmoid and rectum, Synchronous metastases within 6 months after initial diagnoses, ALP alkaline phosphatase, MSI microsatellite instability, MSS microsatellite stable, CD3 density number of tumour-infiltrating CD3 lymphocytes per mm2 tumour tissue microarray, CD8 density number of tumour-infiltrating CD8 lymphocytes per mm2 tumour tissue microarray, CD68 density number of tumour-infiltrating CD68 macrophages per mm2 tumour tissue microarray, OS overall survival, PFS progression-free survival, BSC best supportive care.